VAN-DONEPEZIL TABLET

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

DONEPEZIL HYDROCHLORIDE

Commercializzato da:

VANC PHARMACEUTICALS INC

Codice ATC:

N06DA02

INN (Nome Internazionale):

DONEPEZIL

Dosaggio:

5MG

Forma farmaceutica:

TABLET

Composizione:

DONEPEZIL HYDROCHLORIDE 5MG

Via di somministrazione:

ORAL

Confezione:

100

Tipo di ricetta:

Prescription

Area terapeutica:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

Dettagli prodotto:

Active ingredient group (AIG) number: 0131548001; AHFS:

Stato dell'autorizzazione:

CANCELLED POST MARKET

Data dell'autorizzazione:

2019-08-07

Scheda tecnica

_ _
VAN-Donepezil
Page 1 of 43
_ _
PRODUCT MONOGRAPH
PR VAN-DONEPEZIL
DONEPEZIL HYDROCHLORIDE TABLETS USP
5 AND 10 MG
CHOLINESTERASE INHIBITOR
MANUFACTURER AND DISTRIBUTOR:
Vanc Pharmaceuticals Inc.
Date of Preparation:
Building 152, 11782 River Road
September 10, 2014
Richmond, BC V6X 1Z7
www.vancpharm.com
SUBMISSION CONTROL NUMBER: 177490
_ _
VAN-Donepezil
Page 2 of 43
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT
INFORMATION.................................................................................3
INDICATIONS AND CLINICAL
USE......................................................................................3
CONTRAINDICATIONS.............................................................................................................3
WARNINGS AND
PRECAUTIONS...........................................................................................3
ADVERSE
REACTIONS.............................................................................................................7
DRUG
INTERACTIONS……………………............................................................................14
DOSAGE AND
ADMINISTRATION........................................................................................16
OVERDOSAGE..........................................................................................................................16
ACTION AND CLINICAL
PHARMACOLOGY......................................................................17
STORAGE AND
STABILITY...................................................................................................19
DOSAGE FORMS, COMPOSITION AND
PACKAGING.......................................................19
PART II: SCIENTIFIC
INFORMATION.................................................................................20
PHARMACEUTICAL
INFORMATION...................................................................................20
CLINICAL
TRIALS.................